

Technology Advisory Committee A Interests Register

Ritlecitinib for treating severe alopecia areata in people 12 years and over [ID4007]

Publication Date: 27 March 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Steve O'Brien	Committee Member	Personal	Daughter has alopecia areata	05/09/2023	It was agreed that Steve's declaration would not prevent him from participating in discussions on this appraisal.
Dr Nekma Meah	Clinical Expert	Direct financial interests	<p>Pfizer UK advisory board (Nov 22 and June 23), received personal remuneration.</p> <p>Pfizer educational work on alopecia areata</p> <p>CME outfitters educational talk on Alopecia Areata</p> <p>Steering committee member of GRASS UK</p> <p>Steering committee member of Secure alopecia</p> <p>Support for attending N/A meetings from Eli Lilly and UCB</p>	05/09/2023	It was agreed that Nekma's declaration would not prevent her from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Nekma Meah	Clinical Expert	Direct non-financial interests	Secretary of British Hair and Nail Society	05/09/2023	It was agreed that Nekma's declaration would not prevent her from participating in discussions on this appraisal.
Dr Abby Macbeth	Clinical Expert	Direct non-financial interests	<p>Pfizer- co-author on academic publications of epidemiology of alopecia areata. The studies were funded by Pfizer, but no personal remuneration received.</p> <p>Research committee member for Alopecia UK (charity)</p> <p>NIHR Clinical Research Network East of England regional specialty lead for Dermatology</p> <p>Local principal investigator for clinical trial of different topical drug for alopecia areata (different company- SOTERIOS trial)</p>	05/09/2023	It was agreed that Abby's declaration would not prevent her from participating in discussions on this appraisal.
Dr Patrick De Barr	Committee Member	Direct professional	Baricitinib was developed by Incyte (the company Patrick works for) and is licensed in the same indication as the Pfizer product (alopecia). This drug was licensed to Eli Lilly in Europe and while Incyte are not involved	02/11/2023	It was agreed that Patrick's declaration would prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>in baricitinib in Europe, Patrick feels he is conflicted.</p> <p>Patrick is employed by a company who licence a product (baricitinib) to Eli Lilly who have undergone a recent HTA for alopecia. Patrick feels he is conflicted.</p>	08/12/2023	It was agreed that Patrick's declaration would prevent him from participating in discussions on this appraisal.
Dominic Pivonka	Committee Member	Direct professional Interest	Dominic's employer (AbbVie) has recently announced that it will acquire Immunogen, which has a treatment (mirvetuximab soravtansine) with a Marketing Authorisation Application accepted for review by the European Medicines Agency for patients with folate receptor alpha (FR α)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Immunogen has further phase 2 and phase 3 studies underway for mirvetuximab soravtansine in this disease area.	06/11/2023	It was agreed that Dominic's declaration would prevent him from participating in discussions on this appraisal.
Jaqueline Tomlinson	Committee Member	Direct professional Interest	<ul style="list-style-type: none"> Former chair of Alopecia UK Co-author for Cochrane review: Treatments for alopecia areata: a network meta-analysis 2023 	03/11/2023	It was agreed that Jaqueline's declaration would not prevent her from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
					participating in discussions on this appraisal.